OPINION REVIEW

1. Coronavirus disease 2019 and non-alcoholic fatty liver disease

REVIEW

1. Epigenetic mechanisms of liver tumor resistance to immunotherapy
2. Advances in the management of cholangiocarcinoma
3. Herbal and dietary supplement induced liver injury: Highlights from the recent literature

MINIREVIEWS

1. Challenges in the discontinuation of chronic hepatitis B antiviral agents
2. Liver Kidney Crosstalk: Hepatorenal Syndrome
3. Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions
4. Indeterminate liver lesions on gadoxetic acid-enhanced magnetic resonance imaging of the liver: Case-based radiologic-pathologic review
5. Liver transplantation for benign liver tumors
6. Hepatocellular carcinoma in nonalcoholic fatty liver disease: A growing challenge
7. Addressing hepatic metastases in ovarian cancer: Recent advances in treatment algorithms and the need for a multidisciplinary approach
8. Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice
9. Drug-induced liver injury and COVID-19: A review for clinical practice
10. Probiotics in hepatology: An update

ORIGINAL ARTICLE

1. Development of a risk score to guide targeted hepatitis C testing among human immunodeficiency virus patients in Cambodia
2. Elevated liver enzymes portends a higher rate of complication and death in SARS-CoV-2

META-ANALYSIS

1. Global prevalence of hepatitis B virus serological markers among healthcare workers: A systematic review and meta-analysis